The Deming laboratory is developing new treatment options for patients with colorectal cancer and is developing ways to better identify which patients are more likely to benefit from the available therapies. This talk will describe how they are using cancer genomics, circulating tumor DNA, and patient-derived cancer organoids for this purpose.

Dustin Deming, MD is the ACI/Schwenn Family Associate Professor at the University of Wisconsin School of Medicine and Public Health in the Division of Hematology, Medical Oncology, and Palliative Care in the Department of Medicine, and faculty in the Department of Oncology, McArdle Laboratory for Cancer Research. He is the director of the JD Fluno Colorectal Cancer Precision Medicine Program and co-leader of the Development Therapeutics Program at the University of Wisconsin Carbone Cancer Center. His subspecialty clinical and research focus is in colorectal and pancreatic cancers. He is an early age onset rectal cancer survivor. His research aims to develop innovative treatment strategies for cancer depending on the molecular profile and tumor microenvironment characteristics. As a gastrointestinal medical oncologist, his prior laboratory research has been successfully translated into clinical trials, including NCI/CTEP and industry sponsored clinical trials.

свернуть